Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982301 | 1.00 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL4982294 | 1.00 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL7812322 | 0.96 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL6599822 | 0.90 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL7048718 | 0.90 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL6599817 | 0.90 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL4984681 | 0.89 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL4985137 | 0.89 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL4986365 | 0.89 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL4982773 | 0.89 | MAPK14 (0.61) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114010-A1 | Novel Substituted Imidazole Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-7301021-B2 | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1014976-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20030114452-A1 | Novel substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-6489325-B1 | INHIBITORS OF CSBP/P38, ONE OF SEVERAL KINASES INVOLVED IN A STRESS-RESPONSE SIGNAL TRANSDUCTION, DECREASE THE SYNTHESIS OF A WIDE VARIETY OF PRO-INFLAMMATORY PROTEINS INCLUDING, IL-6, IL-8, GM-CSF, AND COX-2 | SMITHKLINE BEECHAM CORPORATION | 2002-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114452-A1 | Novel substituted imidazole compounds | CREBBP, MAPKAPK2, ATF1 | MAPK14 70/4885 |
| US-20080114010-A1 | Novel Substituted Imidazole Compounds | CREBBP, MAPKAPK2, ATF1 | MAPK14 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.